1887

Abstract

Host anti-toxin immune responses play important roles in disease and outcome. The relationship between host immune and inflammatory responses during severe infection (CDI) and the risk of mortality has yet to be defined. We aimed to investigate the host systemic IgG anti-toxin immune responses, the cytotoxicity of the infecting ribotyped strain, and the host inflammatory markers and their relationship to CDI disease severity and risk of mortality. Inflammatory markers, co-morbidities and CDI outcomes were recorded in a prospective cohort of 150 CDI cases. Serum anti-cytotoxin A (TcdA) and anti-TcdB IgG titres were measured by ELISA and the infecting isolate was ribotyped and the cytotoxin titre assessed. A low median anti-TcdA IgG titre was significantly associated with 30-day all-cause mortality (<0.05). Ribotype 027 isolates were significantly more toxinogenic than other ribotypes (<0.00001). High cytotoxin titres correlated with increased inflammatory markers but also higher anti-TcdA and -TcdB (<0.05) IgG responses resulting in a lower risk of mortality. On multivariate analysis, predictors of mortality were peak white cell count >20×10 l [odds ratio (OR) 11.53; 95 % confidence interval (CI) 2.38–55.92], creatinine concentration >133 µmol l (OR 6.54; 95 % CI 1.47–29.07), Horn’s index >3 (OR 4.09; 95 % CI 0.76–22.18) and low anti-TcdA IgG (OR 0.97; 95 % CI 0.95–0.99), but not ribotype, cytotoxin titre or anti-TcdB IgG. Thus, host pro-inflammatory and humoral responses correlate with the cytotoxin titre of the infecting strain and effective anti-toxin immune responses reduce the risk of mortality.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.058479-0
2013-09-01
2019-10-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/62/9/1453.html?itemId=/content/journal/jmm/10.1099/jmm.0.058479-0&mimeType=html&fmt=ahah

References

  1. Bakker D. , Smits W. K. , Kuijper E. J. , Corver J. . ( 2012; ). TcdC does not significantly repress toxin expression in Clostridium difficile 630ΔErm. . PLoS ONE 7:, e43247. [CrossRef] [PubMed]
    [Google Scholar]
  2. Bauer M. P. , Kuijper E. J. , van Dissel J. T. . European Society of Clinical Microbiology and Infectious Diseases ( 2009; ). European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). . Clin Microbiol Infect 15:, 1067–1079. [CrossRef] [PubMed]
    [Google Scholar]
  3. Cartman S. T. , Kelly M. L. , Heeg D. , Heap J. T. , Minton N. P. . ( 2012; ). Precise manipulation of the Clostridium difficile chromosome reveals a lack of association between the tcdC genotype and toxin production. . Appl Environ Microbiol 78:, 4683–4690. [CrossRef] [PubMed]
    [Google Scholar]
  4. Charlson M. E. , Pompei P. , Ales K. L. , MacKenzie C. R. . ( 1987; ). A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. . J Chronic Dis 40:, 373–383. [CrossRef] [PubMed]
    [Google Scholar]
  5. Cloud J. , Noddin L. , Pressman A. , Hu M. , Kelly C. . ( 2009; ). Clostridium difficile strain NAP-1 is not associated with severe disease in a nonepidemic setting. . Clin Gastroenterol Hepatol 7:, 868–873, e2. [CrossRef] [PubMed]
    [Google Scholar]
  6. Cohen S. H. , Tang Y. J. , Silva J. Jr . ( 2000; ). Analysis of the pathogenicity locus in Clostridium difficile strains. . J Infect Dis 181:, 659–663. [CrossRef] [PubMed]
    [Google Scholar]
  7. Cohen S. H. , Gerding D. N. , Johnson S. , Kelly C. P. , Loo V. G. , McDonald L. C. , Pepin J. , Wilcox M. H. . Society for Healthcare Epidemiology of America Infectious Diseases Society of America ( 2010; ). Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). . Infect Control Hosp Epidemiol 31:, 431–455. [CrossRef] [PubMed]
    [Google Scholar]
  8. He X. , Wang J. , Steele J. , Sun X. , Nie W. , Tzipori S. , Feng H. . ( 2009; ). An ultrasensitive rapid immunocytotoxicity assay for detecting Clostridium difficile toxins. . J Microbiol Methods 78:, 97–100. [CrossRef] [PubMed]
    [Google Scholar]
  9. Horn S. D. , Sharkey P. D. , Bertram D. A. . ( 1983; ). Measuring severity of illness: homogeneous case mix groups. . Med Care 21:, 14–30. [CrossRef] [PubMed]
    [Google Scholar]
  10. Johnson S. . ( 2012; ). Clostridium difficile toxins and severe C. difficile infection. . J Infect Dis 205:, 353–354. [CrossRef] [PubMed]
    [Google Scholar]
  11. Kamiya S. , Reed P. J. , Borriello S. P. . ( 1989; ). Purification and characterisation of Clostridium difficile toxin A by bovine thyroglobulin affinity chromatography and dissociation in denaturing conditions with or without reduction. . J Med Microbiol 30:, 69–77. [CrossRef] [PubMed]
    [Google Scholar]
  12. Kuehne S. A. , Cartman S. T. , Heap J. T. , Kelly M. L. , Cockayne A. , Minton N. P. . ( 2010; ). The role of toxin A and toxin B in Clostridium difficile infection. . Nature 467:, 711–713. [CrossRef] [PubMed]
    [Google Scholar]
  13. Kyne L. , Warny M. , Qamar A. , Kelly C. P. . ( 2000; ). Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. . N Engl J Med 342:, 390–397. [CrossRef] [PubMed]
    [Google Scholar]
  14. Kyne L. , Warny M. , Qamar A. , Kelly C. P. . ( 2001; ). Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. . Lancet 357:, 189–193. [CrossRef] [PubMed]
    [Google Scholar]
  15. McDonald L. C. , Killgore G. E. , Thompson A. , Owens R. C. Jr , Kazakova S. V. , Sambol S. P. , Johnson S. , Gerding D. N. . ( 2005; ). An epidemic, toxin gene-variant strain of Clostridium difficile . . N Engl J Med 353:, 2433–2441. [CrossRef] [PubMed]
    [Google Scholar]
  16. Pépin J. , Valiquette L. , Alary M. E. , Villemure P. , Pelletier A. , Forget K. , Pépin K. , Chouinard D. . ( 2004; ). Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. . CMAJ 171:, 466–472.[PubMed] [CrossRef]
    [Google Scholar]
  17. Rupnik M. , Avesani V. , Janc M. , von Eichel-Streiber C. , Delmée M. . ( 1998; ). A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. . J Clin Microbiol 36:, 2240–2247.[PubMed]
    [Google Scholar]
  18. Steele J. , Chen K. , Sun X. , Zhang Y. , Wang H. , Tzipori S. , Feng H. . ( 2012; ). Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. . J Infect Dis 205:, 384–391. [PubMed] [CrossRef]
    [Google Scholar]
  19. Stubbs S. L. , Brazier J. S. , O’Neill G. L. , Duerden B. I. . ( 1999; ). PCR targeted to the 16S–23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. . J Clin Microbiol 37:, 461–463.[PubMed]
    [Google Scholar]
  20. Thelestam M. , Chaves-Olarte E. . ( 2000; ). Cytotoxic effects of the Clostridium difficile toxins. . Curr Top Microbiol Immunol 250:, 85–96. [CrossRef] [PubMed]
    [Google Scholar]
  21. Thibault A. , Miller M. A. , Gaese C. . ( 1991; ). Risk factors for the development of Clostridium difficile-associated diarrhea during a hospital outbreak. . Infect Control Hosp Epidemiol 12:, 345–348. [CrossRef] [PubMed]
    [Google Scholar]
  22. Warny M. , Vaerman J. P. , Avesani V. , Delmée M. . ( 1994; ). Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. . Infect Immun 62:, 384–389.[PubMed]
    [Google Scholar]
  23. Wilson V. , Cheek L. , Satta G. , Walker-Bone K. , Cubbon M. , Citron D. , Gerding D. N. , Llewelyn M. J. . ( 2010; ). Predictors of death after Clostridium difficile infection: a report on 128 strain-typed cases from a teaching hospital in the United Kingdom. . Clin Infect Dis 50:, e77–e81. [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.058479-0
Loading
/content/journal/jmm/10.1099/jmm.0.058479-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error